Changning Wang received an award from Alzheimer’s Drug Discovery Foundation, under the Neuroimaging and CSF Biomarker Development Program. This funded project is to develop novel PET imaging probes for Receptor-interacting serine/threonine-protein kinase 1 (RIPK1). RIPK1 is a critical signaling protein in the necrosis factor receptor pathway and is a regulator of inflammation and cell death in tissues throughout the body. In the application, Changning and collaborators proposed for the early evaluation of an imaging biomarker of RIPK1 that can be used as a tool to facilitate the clinical development of RIPK1 neurotherapeutics and use in clinical practice.